[et_pb_section fb_built=”1″ admin_label=”Slider” _builder_version=”4.27.4″ _module_preset=”default” width=”100vw” max_width=”100vw” custom_padding=”0px||0px||false|false” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” width=”90%” width_tablet=”100%” width_phone=”100%” width_last_edited=”on|phone” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_slider admin_label=”Slider-Bild” _builder_version=”4.27.4″ _module_preset=”default” background_enable_image=”off” custom_margin=”||0px||false|false” auto=”on” custom_css_slide_title=”animation-name:fadeTop;” custom_css_slide_image=”animation-name:fadeTop;” global_colors_info=”{}”][et_pb_slide _builder_version=”4.27.4″ _module_preset=”default” background_enable_color=”off” background_image=”https:\/\/www.molpath-bw.de\/wp-content\/uploads\/2025\/10\/molekulares-tomorboard-55.jpg” background_enable_image=”on” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][et_pb_slide _builder_version=”4.27.4″ _module_preset=”default” background_enable_color=”off” background_image=”https:\/\/www.molpath-bw.de\/wp-content\/uploads\/2025\/10\/molekulares-tomorboard-91.jpg” background_enable_image=”on” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][et_pb_slide _builder_version=”4.27.4″ _module_preset=”default” background_enable_color=”off” background_image=”https:\/\/www.molpath-bw.de\/wp-content\/uploads\/2025\/10\/molekulares-tomorboard-149.jpg” background_enable_image=”on” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][et_pb_slide _builder_version=”4.27.4″ _module_preset=”default” background_enable_color=”off” background_image=”https:\/\/www.molpath-bw.de\/wp-content\/uploads\/2025\/10\/molekulares-tomorboard-159.jpg” background_enable_image=”on” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][\/et_pb_slider][et_pb_text admin_label=”Slider-Headline” _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#1D1D1B” text_font_size=”28px” text_line_height=”1.2em” header_4_font=”|600|||||||” header_4_text_color=”#1D1D1B” header_4_font_size=”30px” header_4_line_height=”1.2em” background_color=”RGBA(255,255,255,0)” use_background_color_gradient=”on” background_color_gradient_direction=”91deg” background_color_gradient_stops=”#ffffff 0%|rgba(0,196,163,0) 98%” positioning=”absolute” position_origin_a=”bottom_left” z_index=”500″ width=”100%” custom_padding=”2%|5%|1%|5%|false|true” animation_style=”slide” animation_direction=”bottom” animation_intensity_slide=”5%” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Inhalt” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||false|false” custom_padding=”0px||40px||false|false” animation_style=”fade” locked=”off” collapsed=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” link_text_color=”#1D1D1B” header_4_text_color=”#1D1D1B” custom_margin=”||0px||false|false” custom_padding=”||||false|false” global_colors_info=”{}” link_text_color__hover_enabled=”on|desktop” link_text_color__hover=”#0082B0″]<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″ locked=”off”]<\/p>\n
The identification of molecular biomarkers is only useful if they are interpreted in a clinical context and on the basis of current scientific evidence.
\nIf therapy-relevant biomarkers are detected, the findings are presented to the Molecular Tumor Board (MolIT) after consultation with the treating colleagues. There, possible treatment options are discussed in an interdisciplinary manner, taking into account all pathological and molecular pathological findings as well as the course of the disease to date. The treating physicians can participate online; upon request, we can present the case based on the current physician’s letter. The tumor board’s decision is usually available within a few days.<\/p>\n
[\/et_pb_text][et_pb_text module_class=”extern” _builder_version=”4.27.4″ _module_preset=”default” locked=”off” global_colors_info=”{}”]<\/p>\n